A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma

By sjmartinez • June 30, 2023

Cho BC, Penkov K, Bondarenko I, Kurochkin A, Pikiel J, Ahn HK, Korożan ME, Osipov M, Odintsova S, Braiteh F, Ribas A, Grilley-Olson JE, Lugowska I, Bonato V, Damore MA, Yang W, Jacobs IA, Bowers M, Li M, Johnson ML. A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma. ESMO Open. 2023 Jun 27;8(4):101589. doi: 10.1016/j.esmoop.2023.101589. Epub ahead of print. PMID: 37385154.

Tags: Hematology/Oncology, non-small-cell lung cancer, PD-1, phase I, Publications, sasanlimab, urothelial carcinoma

PAK4 orchestrates dual transcriptional and post-translational repression of E-cadherin to promote epithelial-to-mesenchymal transition and invasiveness in pancreatic cancer

Kim KJ, Lee CH, Nam M, Na HY, Sung JH, Park BR, Hwang SH, Park W, Seo J, Kang M, Jung EH, Kim SA, Suh[...]

Discussing lung cancer management options in the emergency department

Moghanaki D, Goldman J, Weingrow D, Hendey GW. Discussing lung cancer management options in the emergency department. Emerg Med J. 2026 Oct 30:emermed-2026-216560. doi: 10.1136/emermed-2026-216560.[...]

p53 activation via pharmacologic MDM2 inhibition constrains exhaustion and enhances antitumor function of human CD8+ T cells

Boix de Jesus A, Dao HB, Imani A, Rodriguez GA, Shehata MS, Chandran RR, Fine SA, Lim SY, To M, Lofftus SY, Pedroncelli N, Eilber[...]